Regulatory Roundup: USP to Make Pharmacopeial Forum Free Online, And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: USP to Make Pharmacopeial Forum Free Online, And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeial Convention (USP) is transitioning the Pharmacopeial Forum (PF) to a free, online resource as of January 2011. The forum includes proposals for new and revised standards for the official United States Pharmacopeia–National Formulary (USP–NF). The new PF will include only proposals for which USP is seeking public comment, making it easier for users to identify and respond to these proposals, according to a USP press release on the subject. For example, the new version will include articles about standards development, how to use PF, in–process revision, proposed interim revision announcements (IRAs), Pharmacopeial Discussion Group harmonization proposals (Stage 4), and Stimuli articles.

Some items that are currently published in PF will not appear in the new free online version. However, they will be made publicly available on USP’s website. These include policies and announcements, final IRAs, IRA reference standard information, Errata, previous PF proposals still pending, and canceled proposals. The new PF will provide a list of links noting where to find these relocated items.

 

PDA and ISPE are hosting a Washington, DC-based ICH workshop Oct. 6–8, 2010, covering implementation of the quality trio, Q8 Pharmaceutical Development, Q9 Pharmaceutical Risk Management, and Q10 Pharmaceutical Quality System. The workshop will feature members of the ICH Quality Implementation Working Group, including representatives from FDA and EMA, and include breakout sessions on design space, control strategy, quality system, and risk management. Industry is encouraged to attend.

 

The International Pharmaceutical Supply-Chain Consortium, Rx-360, received good news last week when the Federal Trade Commission said it would not recommend challenging industry’s plans to implement joint supplier and audit programs. Rx-360 has been working for the past 18 months to encourage the sharing of information about supplier audits throughout the global pharmaceutical manufacturing industry.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here